Working with real-world evidence-based data can pose difficulties, both when collecting and analyzing the information, but redesigned incentives could help drive entities to provide more information, said Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.
Working with real-world evidence-based data can pose difficulties, both when collecting and analyzing the information, but redesigned incentives could help drive entities to provide more information, said Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington.
Transcript (slightly modified)
What are the challenges of working with real-world evidence-based data? Do the benefits outweigh the negatives?
The big issue, as the report brings out, is the potential for bias. You don’t have the advantage that you do in a randomized clinical trial to sort of limit the amount of bias, so we have methodological techniques to address that that are not perfect, but we can still learn from real-world data.
At the same time, you can’t apply those techniques unless you have the data, so sadly the infrastructure that we have in America as a fragmented, complicated healthcare system means interoperability across systems is limited, so that’s a real challenge. The infrastructure standards and so on are a big challenge too, developing the data we need to follow how medicines and other things are used over time, but the other big issue is, you could say we’ve had this need for 10 years, why haven’t we seen more?
I think it has to do with economics, with incentives to produce the information. Any given entity that’s competing with other entities, so pharmaceutical manufacturers have a limited incentive to produce the data in some instances, and payers have a limited incentive, because other people can then free ride on their information, so we have incentive problems. We need to somehow find ways to encourage people and reward people who do provide the information.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More